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Abstract: Zika virus (ZIKV), a mosquito-borne transplacentally transmissible flavivirus, is an
enveloped virus with an ~10.8 kb plus-strand RNA genome that can cause neurological disease.
To facilitate the identification of potential antivirals, we developed two reporter-expressing ZIKVs,
each capable of expressing an enhanced green fluorescent protein or an improved luminescent
NanoLuc luciferase. First, a full-length functional ZIKV cDNA clone was engineered as a bacterial
artificial chromosome, with each reporter gene under the cap-independent translational control of
a cardiovirus-derived internal ribosome entry site inserted downstream of the single open reading
frame of the viral genome. Two reporter-expressing ZIKVs were then generated by transfection
of ZIKV-susceptible BHK-21 cells with infectious RNAs derived by in vitro run-off transcription
from the respective cDNAs. As compared to the parental virus, the two reporter-expressing
ZIKVs grew to lower titers with slower growth kinetics and formed smaller foci; however, they
displayed a genome-wide viral protein expression profile identical to that of the parental virus,
except for two previously unrecognized larger forms of the C and NS1 proteins. We then used the
NanoLuc-expressing ZIKV to assess the in vitro antiviral activity of three inhibitors (T-705, NITD-008,
and ribavirin). Altogether, our reporter-expressing ZIKVs represent an excellent molecular tool for
the discovery of novel antivirals.
Keywords: Zika virus; infectious cDNA; reporter-expressing virus; green fluorescent protein;
luciferase; viral protein expression profile; antiviral
1. Introduction
Zika virus (ZIKV) is a mosquito-borne arbovirus belonging to the genus Flavivirus, family
Flaviviridae [1]. Within the genus, ZIKV is closely related to other clinically important mosquito-borne
flaviviruses, such as dengue (DENV), Japanese encephalitis (JEV), West Nile (WNV), and yellow fever
(YFV) viruses, as well as several medically significant tick-borne flaviviruses, including tick-borne
encephalitis and Powassan viruses [2]. In humans, ZIKV is spread horizontally by blood-sucking
mosquitoes of the genus Aedes (e.g., A. aegypti and A. albopictus) and through sexual contact, but it can
also be passed vertically from a pregnant woman to her fetus in utero [3–8]. While uncommon, ZIKV
transmission can also occur via blood transfusion and breastfeeding [9,10]. The clinical outcome of
ZIKV infection varies significantly, with the estimated prevalence of asymptomatic cases ranging from
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~30% to >85% [11], depending on a combination of viral strain, study population, and environmental
conditions at a given time [12–14]. Symptomatic ZIKV infection typically presents as a mild self-limiting
illness with nonspecific flu-like symptoms [7,15], but it can also lead to a range of severe neurological
disorders, such as Guillain-Barré syndrome (GBS) in adults and congenital Zika syndrome (CZS)
in neonates [16–20]. However, neither effective drugs nor vaccines are available for the control of
ZIKV infection.
ZIKV is an ~50 nm diameter particle that has an outer lipid bilayer embedded with 180 copies
of each of the two well-defined surface proteins, membrane (M) and envelope (E) [21,22]. Inside
the particle is an ill-defined nucleocapsid formed by the association of multiple copies of the capsid
(C) protein with one copy of the viral genome [23]. The ZIKV genome is a linear, single-stranded,
positive-sense RNA of approximately 10,800 nucleotides (nt) [24] and contains a 7-methylguanosine
(m7G) cap at the 5′ end, but no poly(A) tail at the 3′ end [25]. It has a single long open reading frame
(ORF) flanked by the two short highly-structured untranslated regions (5′ and 3′ UTRs) that play
key regulatory roles in viral translation and RNA replication through 5′–3′ long-distance RNA-RNA
interactions [1,26]. The ORF encodes a large polyprotein that is processed by both host cell- and
virus-encoded proteases to produce at least 10 major proteins: three structural (C, prM [precursor of
M], and E) and seven nonstructural (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) [12]. The viral
genomic RNA serves not only as a template for both translation and RNA replication, but also as
a substrate for degradation by cellular 5′ to 3′ exoribonucleases that stops at a higher-order RNA
structure within the 3′UTR, thereby producing small non-coding RNAs [27,28]. These non-coding
RNAs counteract host cell antiviral responses [29].
ZIKV and other flaviviruses share a similar replication strategy [1]. Once bound to the cell
surface, the virion is taken up by viral protein E-mediated endocytosis [30]. The internalized
virion travels to an endosomal compartment where the acidic environment induces large
conformational changes in the E proteins, leading to fusion of the viral membrane with the
endosomal membrane and release of the viral genomic RNA into the cytoplasm [31,32]. After
initial translation of the genomic RNA, viral RNA replication takes place inside virus-induced,
specialized membranous structures derived from the endoplasmic reticulum (ER) [33] and is
catalyzed by two bidomain multifunctional proteins: (i) NS3, comprising a serine protease domain
(requiring NS2B as a cofactor) and an RNA helicase/NTPase/RTPase domain [34–38] and (ii) NS5,
comprising a methyltransferase/guanylyltransferase domain and an RNA-dependent RNA polymerase
domain [39–44]. Viral assembly is initiated by budding of the viral genomic RNA and C proteins
into the ER lumen to incorporate the prM and E proteins into a budding immature particle [45].
The immature virion then usurps the cellular secretory pathway to exit the cell [46]; during this
process, the prM proteins are processed into the mature M proteins, followed by major structural
rearrangements in the M and E proteins prior to viral release from the cell [47].
The ancestral prototype strain of ZIKV designated MR-766 was first isolated from a naturally
infected symptomatic rhesus macaque in the Zika forest of Uganda in 1947 [48]. Over the half-century
following its discovery, ZIKV circulated only in the tropical and subtropical regions of two connected
continents, Africa and Asia, without posing a significant threat to humans [7,49]. In 2007, however, it
first emerged outside Africa and Asia, causing a relatively small but historically important outbreak
in Yap Island in the western North Pacific, with ~5000 people estimated to be infected [15,50,51].
From there, the virus moved eastward across the Pacific Ocean, causing a large outbreak of an
estimated ~30,000 infections in French Polynesia and other nearby islands in the central South Pacific
in 2013–2014 [52–54], and then a massive outbreak of an estimated >200,000 infections in the Americas
and their adjacent islands in 2015–2016 [55–57]. While the Yap Island outbreak was characterized by a
mild illness with fever, rash, arthralgia, and/or conjunctivitis, the two French Polynesian and American
outbreaks were the first to reveal an association between ZIKV infection and severe neurological
complications, such as GBS and CZS [7,58,59]. Because of its impact on global public health, ZIKV is
now a priority pathogen for the development of therapeutics and vaccines.
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In the present study, we created two reporter-expressing ZIKVs to provide an ideal toolkit for
monitoring viral replication with no need for secondary methodologies in order to facilitate the
screening and testing of antiviral drug candidates. In each case, we engineered a full-length infectious
cDNA clone of ZIKV MR-766 to insert a reporter expression cassette composed of an enhanced
green fluorescent protein (eGFP) or improved luminescent NanoLuc luciferase (nLUC) gene and
a cardiovirus-derived internal ribosome entry site (IRES) controlling its expression. We recovered
two reporter-expressing ZIKVs from the respective cDNAs, examined their biological properties,
and used them to evaluate the in vitro antiviral activity of three inhibitors. Our reporter-expressing
ZIKVs provide a new means not only for the discovery of therapeutics, but also for the study of
viral replication.
2. Materials and Methods
2.1. Cell Culture
BHK-21 cells were cultured as monolayers in α-modified minimal essential medium (MEM)
containing 10% fetal bovine serum (FBS), 2 mM L-glutamine, 1 ×MEM vitamin solution, and 10 U/mL
penicillin-streptomycin at 37 ◦C with 5% CO2 in a humidified incubator [60]. All cell culture reagents
were purchased from Gibco-Life Technologies, Carlsbad, CA, USA.
2.2. DNA Cloning
We constructed two reporter-encoding full-length cDNA clones (designated pZIKV-eGFP and
pZIKV-nLUC) of ZIKV MR-766, using our previously generated infectious cDNA clone pBac/MR-766
(here called pZIKV) as the parental construct [12]. The two cDNA clones were engineered by standard
recombinant DNA techniques and were finally purified by CsCl banding. The nucleotide sequence
of the PCR-amplified regions was verified by sequencing and the overall integrity of the full-length
cDNA clones was confirmed by extensive restriction mapping. The oligonucleotide primers used in
this study are summarized in Table 1.
Table 1. Oligonucleotide primers used for the construction of reporter-encoding full-length ZIKV
cDNA clones.
Oligonucleotide Sequence (5′→3′) Polarity
ORF3f AAACGGACCGGGATCCCTTATAGGGCACAGAC Sense
ORF3r TTTGAATTCACACTAAAATTGGTGCTTACAA Antisense
3UTRf AAAATGCATGCACCAATTTTAGTGTTGTCAGG Sense
3UTRr TTTCCGCGGAGGGCGGCCGCGTATGTCGCGTT Antisense
FORf GTGGAAGGAGCTGGGGAAACGCAAGCGGCC Sense
POLr TGGCTTCACAACGCAGGCAGCTCCACTGACCGCCA Antisense
POLf TGGCGGTCAGTGGAGCTGCCTGCGTTGTGAAGCCA Sense
REVr CCAAGTGGTGCGGGGTCTGTGCCCTATAAG Antisense
EGFPf ACAACCATGGTGAGCAAGGGCGAGGAGCTGTT Sense
EGFPr TGCATGCATTCATTAACCGTCGACTGCAGAATT Antisense
First, pZIKV-nLUC was constructed initially by amplifying two cDNA fragments of pZIKV
by PCR. The first amplicon (PCR I), produced using primers ORF3f and ORF3r, was the 200-bp
fragment comprising the 3′-terminal region of the viral ORF, followed by the 5′ end portion of the
viral 3′UTR. The second amplicon (PCR II), produced using primers 3UTRf and 3UTRr, was the
483-bp fragment spanning the entire viral 3′UTR. In addition, the 1113-bp cDNA fragment containing
the encephalomyocarditis virus (EMCV) IRES-driven nLUC expression cassette was obtained from
pJEV-nLUC (Yun, SI and Lee, YM; unpublished) by digestion with EcoRI and NsiI. The 188-bp
RsrII-EcoRI fragment of PCR I was then subcloned into pRS2, along with the 1113-bp EcoRI-NsiI
fragment of the nLUC expression cassette by using RsrII and NsiI, thereby producing pRS/Luc-1. Next,
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the 471-bp NsiI-SacII fragment of PCR II was inserted downstream of the EMCV IRES-driven nLUC
expression cassette in pRS/Luc-1 using the same two restriction enzymes, thereby producing pRS/Luc-2.
Finally, the 1735-bp BamHI-BsiWI fragment of pRS/Luc-2 was ligated with the 17971-bp BsiWI-BamHI
fragment of pZIKV, creating pZIKV-nLUC. For the replication-incompetent pZIKV-nLUCPOL− mutant,
in which the catalytic site of the NS5 polymerase domain was inactivated by site-directed mutagenesis
(changing GDD to GAA), two overlapping cDNA fragments were first amplified by PCR with two
primer pairs, FORf + POLr and POLf + REVr. The resulting two fragments were then fused by a second
round of PCR with the outer primers FORf and REVr. Finally, the 1372-bp MluI-BamHI fragment of the
resulting amplicons was ligated with the 18334-bp BamHI-MluI fragment of pZIKV-nLUC, creating
pZIKV-nLUCPOL−.
For the construction of pZIKV-eGFP, we first amplified a 786-bp cDNA fragment corresponding to
the complete coding sequence of eGFP from pJEV-eGFP [60] by PCR, using primers EGFPf and EGFPr.
The 521-bp nLUC ORF was cut out from pRS/Luc-2 by digestion with NcoI and NsiI and replaced by
ligating the 773-bp NcoI-NsiI fragment of the eGFP amplicon in its place, thereby producing pRS/eGFP.
As was done for the construction of pZIKV-nLUC, the 1987-bp BamHI-BsiWI fragment of pRS/eGFP
was finally ligated with the 17971-bp BsiWI-BamHI fragment of pZIKV, creating pZIKV-eGFP.
2.3. In Vitro Transcription
Run-off transcription was carried out to synthesize full-length ZIKV RNAs in vitro from a cloned
cDNA of pZIKV or its derivatives [12,61]. In short, each full-length ZIKV cDNA clone was first
linearized by digestion with PsrI (SibEnzyme, West Roxbury, MA, USA). In all cases, ~200 ng of the
linearized cDNA template was mixed in a 25-µL transcription reaction with 20 U SP6 RNA polymerase,
0.6 mM cap analog m7GpppA, 1 mM each NTP, 10 mM dithiothreitol, 40 U RNaseOUT, and the
buffer supplied by the manufacturer (New England Biolabs, Ipswich, MA, USA). The reactions were
first allowed to proceed at 37 ◦C for 1 h and further incubated for an additional 30 min with 10 U
DNase I to degrade the template cDNA. RNA transcripts were quantified by adding 0.5 µM [3H]UTP
(PerkinElmer, Boston, MA, USA) per reaction and calculating the amount of its incorporation into RNA
based on the binding of RNA to DE81 paper (Whatman, Maidstone, United Kingdom). The integrity
of the RNA transcripts was examined by running an aliquot of each reaction on a 0.6% agarose gel and
visualizing the bands by ethidium bromide staining.
2.4. RNA Transfection
BHK-21 cells were transfected with in vitro-transcribed RNAs using the ECM 830 electroporation
system (BTX, San Diego, CA, USA) as reported previously [61,62]. In brief, subconfluent cell monolayers
were trypsinized to yield a single-cell suspension, washed three times with cold phosphate-buffered
saline (PBS), and then resuspended in cold PBS at 2 × 107 cells/mL. A 400-µL aliquot of the cell
suspension was mixed with 2 µg of RNA on ice. The RNA-cell mixture was then transferred to
a 2-mm-gap cuvette (BTX) and immediately pulsed five times at 980 V with a 99-µs pulse length.
The electroporated cells were diluted to 1 mL with complete cell culture medium and kept at room
temperature for 10 min to recover from the electric pulses.
2.5. Infectious Center Assay
An infectious center assay was used to determine the specific infectivity of run-off RNA transcripts
derived from pZIKV, pZIKV-eGFP, or pZIKV-nLUC. First, BHK-21 cells were transfected with
in vitro-transcribed RNAs as described above, serially diluted 1:10 in 1 mL of complete cell culture
medium, and placed on naïve BHK-21 cells grown in a 6-well plate (5 × 105 cells/well). Cells were
allowed to attach to the plates for 6 h, after which the culture medium was replaced with an agar
overlay composed of 0.5% SeaKem LE agarose and 10% FBS in MEM. Plates were then incubated
at 37 ◦C with 5% CO2 for 4 days before the infectious foci were visualized by immunostaining [62].
Specifically, cells were first fixed with 7% formaldehyde in PBS overnight, followed by three washes
Viruses 2020, 12, 572 5 of 24
(10 min each) with PBS. The fixed cells were then permeabilized with 0.25% Triton X-100 in PBS
for 10 min and incubated for 2 h with a 1:1000 dilution of a polyclonal rabbit α-NS3 antiserum [12].
After three washes with PBS, the primary antibody-treated cells were again incubated for 2 h with a
1:1000 dilution of horseradish peroxidase-conjugated goat α-rabbit IgG (Jackson ImmunoResearch
Laboratories, West Grove, PA, USA). The secondary antibody-labeled cells were then washed three
times with PBS before being developed by incubation with 3,3′-diaminobenzidine (Vector Laboratories,
Burlingame, CA, USA).
2.6. Immunoblot Analysis
A series of immunoblot analyses was employed to compare the overall viral protein expression
profile generated from the infectious RNAs derived from pZIKV, pZIKV-eGFP, or pZIKV-nLUC:
BHK-21 cells were transfected with in vitro-synthesized RNAs and seeded in a 6-well plate at a
density of 3 × 105 cells/well. Every day for 4 days, cells were harvested with 200 µL per well of cell
lysis buffer (80 mM Tris-HCl [pH 6.8], 2% sodium dodecyl sulfate [SDS], 100 mM dithiothreitol, 10%
glycerol, and 0.2% bromophenol blue). Equal volumes of whole cell lysates were boiled for 5 min
and separated by SDS-polyacrylamide gel electrophoresis (PAGE). Resolved proteins on the gel were
blotted electrophoretically onto a polyvinylidene difluoride membrane using a Trans-Blot SD Semi-Dry
Transfer Cell (Bio-Rad Laboratories, Hercules, CA, USA). After blotting, the membrane was blocked
for 1 h in wash buffer (0.2% Tween 20 in PBS) with 5% non-fat dry milk and washed three times (all
washes 10 min each). The blocked membrane was then probed for a protein of interest for 2 h in
staining buffer (0.5% non-fat dry milk in wash buffer), with one of the following polyclonal rabbit
antisera at the indicated dilution [12,63]: α-C (1:100), α-M (1:1000), α-E (1:250), α-NS1 (1:1000), α-NS2B
(1:100), α-NS3 (1:1000), α-NS4A (1:1000), α-NS4B (1:1000), α-NS5 (1:1000), and α-GAPDH (1:5000).
The primary antibody-treated membrane was washed three times, followed by a 2-h incubation in
staining buffer with a 1:1000 dilution of alkaline phosphatase-conjugated goat α-rabbit IgG (Jackson
ImmunoResearch Laboratories). The secondary antibody-labeled membrane was washed three times
with wash buffer and rinsed once with PBS. Finally, the membrane was incubated in a developing
solution containing 5-bromo-4-chloro-3-indolyl-phosphate and nitroblue tetrazolium (MilliporeSigma,
St. Louis, MO, USA).
2.7. Fluorescence Microscopy
The expression of eGFP was analyzed in BHK-21 cells both after the transfection of cDNA-derived
viral RNAs and after the infection of cDNA-derived recombinant viruses. In the first case, cells were
electroporated with 2 µg of viral RNAs, then plated in a 4-well chamber slide (1 × 105 cells/well)
and incubated for 40 h. In the second case, cells were first seeded in a 4-well chamber slide (1 ×
105 cells/well) for 12 h, then infected with each of recombinant viruses at a multiplicity of infection
(MOI) of 1 and incubated for 40 h. In both cases, the cells were fixed for 10 min with 4% formaldehyde
in PBS, washed twice with PBS, and mounted in an anti-fading solution (Dako, Glostrup, Denmark).
Fluorescence images were recorded with an LSM-710 confocal microscope (Carl Zeiss, Jena, Germany).
2.8. Luciferase Assay
The activity of nLUC was examined in BHK-21 cells both after the transfection of cDNA-derived
viral RNAs and after the infection of cDNA-derived recombinant viruses. For the transfection
experiments, cells were electroporated with 2 µg of viral RNAs, then split into a 6-well plate (3 ×
105 cells/well) and incubated for 4 days. For the infection experiments, cells were first placed in a
6-well plate (3 × 105 cells/well) for 12 h, then infected with each of recombinant viruses at a MOI of 1
and incubated for 4 days. In both types of experiment, the nLUC assay was performed according to
the protocol from the manufacturer of the Nano-Glo Luciferase Assay (Promega, Madison, WI, USA).
In brief, cells were harvested using 200 µL per well of Assay Buffer at various time points throughout
incubation. The nLUC assay was performed by combining 10 µL of each cell lysate with 10 µL of
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Assay Buffer and 20 µL of Assay Substrate in a 96-well plate. Luminescence readings were obtained
with a Synergy HT microplate reader (BioTek Instruments, Winooski, VT, USA).
2.9. Antiviral Testing
Three compounds used in this study were: (i) T-705, dissolved in dimethyl sulfoxide (DMSO)
to make a stock solution of 20 mg/mL and tested at final concentrations of 0 (DMSO alone), 1, 4, 20,
and 100 µg/mL; (ii) NITD-008, dissolved in DMSO to make a stock solution of 10 mM and tested
at final concentrations of 0 (DMSO alone), 1, 4, 20, and 100 µM; and (iii) ribavirin, dissolved in cell
culture medium to make a stock solution of 2 mg/mL and tested at final concentrations of 0, 8, 40, 200,
and 1000 µg/mL. To examine the cell toxicity of the compounds, BHK-21 cells were placed in a 96-well
plate (1 × 104 cells/well) and cultivated for 48 h in 100 µL of complete cell culture medium without
or with one of the compounds at the concentrations indicated. Cell toxicity was monitored using
the CellTiter-Blue Cell Viability Assay (Promega) by adding 20 µL per well of CellTiter-Blue Reagent,
incubating the plate at 37 ◦C with 5% CO2 for 30 min, and then recording fluorescence readings with
a Synergy HT microplate reader (BioTek Instruments) equipped with a 560-nm excitation filter and
a 590-nm emission filter. To analyze the antiviral activity of the compounds against ZIKV infection
in vitro, BHK-21 cells were seeded into a 96-well plate (1 × 104 cells/well) for 12 h, infected with
rZIKV-nLUC at a MOI of 0.1 for 1 h, and then incubated for 48 h in 100 µL of complete cell culture
medium in the absence or presence of a compound at the concentrations indicated. At the end of
the incubation, antiviral activity was evaluated by measuring both the level of extracellular virus
production in culture supernatants using the immunofocus assay reported previously [12] and the
level of intracellular nLUC expression in cell lysates using the luciferase assay described above.
3. Results
3.1. Construction of Two Reporter-Encoding Full-Length ZIKV cDNA Clones
We selected two reporters for the development of reporter-expressing ZIKVs: an enhanced green
fluorescent protein (eGFP) and an improved luminescent NanoLuc luciferase (nLUC). They each
have particular attributes that make them uniquely valuable: (1) eGFP (~29 kDa) is a genetically
engineered variant of the original jellyfish-derived GFP that is codon-optimized for higher protein
expression in mammalian cells and contains chromophore mutations for brighter fluorescence [64,65].
The newly acquired properties of eGFP, together with its intrinsic fluorescence in the absence of
any substrate or cofactor, make it a convenient marker for visual monitoring of viral replication in
a variety of mammalian cells. (2) nLUC (~19 kDa) is a small, ATP-independent, and thermostable
luciferase that is brighter than the traditional Photinus or Renilla luciferase, with reduced background
luminescence [66]. These unique properties of nLUC make it an attractive reporter for precise
quantification of viral replication.
As illustrated schematically in Figure 1, we constructed two new full-length ZIKV cDNA clones
encoding eGFP (pZIKV-eGFP) or nLUC (pZIKV-nLUC), based on a single-copy bacterial artificial
chromosome (BAC) vector, using our previously developed functional BAC clone of ZIKV MR-766
(pZIKV) [12]. The parent pZIKV contains a complete cDNA copy of the viral genomic RNA, flanked
on each side by a 5′ SP6 promoter sequence and a 3′ PsrI restriction site for the production of run-off
RNA transcripts with authentic 5′ and 3′ ends of the viral genome. We kept the single ZIKV ORF
intact and under the cap-dependent translational control of its own 5′UTR as the first cistron and
inserted a reporter expression cassette as the second cistron between the end of the viral ORF and
the beginning of the viral 3′UTR. The reporter expression cassette consists of the coding sequence
for eGFP (768 nt) or nLUC (516 nt) under the cap-independent translational control of a 619-nt IRES
from EMCV. The insertion of such a reporter expression cassette therefore increases the genome size of
recombinant ZIKVs (indicated by the prefix “r”) recoverable from their corresponding cDNAs: from
10,807 nt (rZIKV) to 12,194 nt (rZIKV-eGFP) or 11,942 nt (rZIKV-nLUC).
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Figure 1. Schematic representation of two reporter-encoding full-length ZIKV cDNA clones. The top
panel shows the genome structure of the parental ZIKV (rZIKV) recovered from its full-length cDNA
clone (pZIKV). The two bottom panels depict the genome structures of two reporter-encoding ZIKVs
(rZIKV-eGFP and rZIKV-nLUC) rescued from their respective full-length cDNA clones (pZIKV-eGFP
and pZIKV-nLUC). In both constructs, each reporter gene driven by the encephalomyocarditis virus
(EMCV) internal ribosome entry site (IRES) is inserted after the stop codon of the viral open reading
frame (ORF) at the beginning of the 3′ untranslated region (UTR). The nucleotide sequences provided
below the three full-length cDNA clones correspond to the 5′ SP6 promoter (magenta uppercase) and
3′ unique PsrI restriction site (red uppercase) engineered immediately upstream and downstream of
the viral genome (black lowercase), respectively. Also, the arrowheads marked below the nucleotide
sequences indicate the transcription start and run-off sites for in vitro transcription. The genome size
of each recombinant virus is shown, as is the insert size of each reporter gene expression cassette.
3.2. Production of Infectious RNA Transcripts from Two Reporter-Encoding Full-Length ZIKV cDNA Clones
We assessed the specific infectivity of RNA transcripts derived from each of two reporter-encoding
full-length ZIKV cDNA clones (pZIKV-eGFP and pZIKV-nLUC), as compared to those derived
from the parent pZIKV. In the case of all three clones, RNAs were synthesized in vitro by run-off
transcription of each PsrI-linearized cDNA template and equal amounts of these RNAs were transfected
into ZIKV-susceptible BHK-21 cells for infectious center assays. At 96 h post-transfection (hpt),
the infectious centers of foci were visualized by immunostaining with a rabbit α-NS3 antiserum.
On average, the infectivity of pZIKV-derived RNAs was estimated to be 7.1 × 105 focus-forming units
(FFU) per µg, whereas the infectivities of the RNAs derived from both pZIKV-eGFP and pZIKV-nLUC
were equally reduced by ~1 log to a range of 9.0–9.8 × 104 FFU/µg (Figure 2A). With respect to focus
morphology, there was an ~5-fold decrease in the size of the NS3-positive foci observed in cells
transfected with RNAs derived from pZIKV-eGFP and pZIKV-nLUC, when compared to those in cells
transfected with pZIKV-derived RNAs (Figure 2B).
We next determined the amount of infectious recombinant ZIKVs released into culture supernatants
from RNA-transfected BHK-21 cells. Culture media were harvested daily for 4 days and virus yields
were titrated by immunofocus assays on naïve BHK-21 cells using the rabbit α-NS3 antiserum.
The parent rZIKV accumulated rapidly, achieving a peak titer of 2.2 × 106 FFU/mL at 48 hpt, which then
dropped over the next 48 h to 2.0 × 105 FFU/mL at 96 hpt because of a lack of viable cells remaining
(Figure 2C). On the other hand, both rZIKV-eGFP and rZIKV-nLUC accumulated at a nearly identically
slow-but-steady rate for the entire 4 days, reaching their maximum titers of 0.9–1.5 × 106 FFU/mL at 96
hpt (Figure 2C). This delay in virus production is in line with the observed decreases in RNA infectivity
(Figure 2A) and focus size (Figure 2B). Altogether, these results indicate that RNA transcripts derived
from each of our eGFP- and nLUC-encoding full-length ZIKV cDNA clones are equally functional,
having a specific infectivity of ~105 FFU/µg, about one log lower than those derived from the parental
ZIKV cDNA clone (as a result of the increase in viral genome size).
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Figure 2. Recovery of two infectious reporter-encoding ZIKVs. BHK-21 cells were mock-transfected
or transfected with 2 µg of run-off RNA transcripts synthesized in vitro from each of the three
PsrI-linearized cDNA templates, namely pZIKV, pZIKV-eGFP, and pZIKV-nLUC. (A) RNA infectivity.
The specific infectivity of run-off RNA transcripts was determined by infectious center assays involving
immunostaining the infectious foci at 96 h post-transfection (hpt) with a rabbit α-NS3 antiserum.
Data are presented as focus-forming units (FFU) per µg. (B) Focus morphology. Representative focus
images are shown, with the average focus diameters (mean ± standard deviations [SD]) estimated by
counting 20 randomly picked foci from two independent experiments. (C) Virus yield. The level of
virus production was determined by immunofocus assays involving harvesting culture supernatants
at the indicated time points after RNA transfection and titrating the amounts of infectious virions on
naïve BHK-21 cells. Black single asterisks indicate the time points at which >90% of cells were detached
from the culture plate as a result of virus-induced cell death. Error bars represent standard deviations
of two independent experiments.
3.3. Probing of Viral Protein Accumulation During ZIKV Genomic RNA Replication
We compared the protein expression profile and accumulation kinetics of almost all the viral gene
products made from the infectious RNA derived from each of our two reporter-encoding full-length
ZIKV cDNA clones and from their parental cDNA clone for comparison. To this end, BHK-21 cells
were mock-transfected or transfected with an equal amount of infectious RNA transcribed in vitro
from pZIKV-eGFP, pZIKV-nLUC, or pZIKV. Following transfection, the cells were harvested daily
for 4 days. Equal amounts of whole-cell lysates were then separated on polyacrylamide gels under
denaturing and reducing conditions, followed by immunoblotting, with each of our nine previously
well-characterized ZIKV-specific polyclonal rabbit antisera [12], i.e., a first set of three (α-C, α-M,
and α-E) capable of detecting all of three viral structural proteins (Figure 3) and a second set of six
(α-NS1, α-NS2B, α-NS3, α-NS4A, α-NS4B, and α-NS5) identifying six of the seven viral nonstructural
proteins (all except NS2A) (Figure 4). Also, a rabbit α-GAPDH antiserum was used to detect the
cellular housekeeping GAPDH protein as a sample loading control for our immunoblotting.
Our series of immunoblot analyses revealed both expected and unexpected results. As expected,
in cells transfected with pZIKV-derived RNA and in those transfected with RNA derived from
pZIKV-eGFP or pZIKV-nLUC, we observed a similar overall expression profile of the mature ZIKV
proteins, together with related species that were presumed to represent cleavage intermediates or
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further cleavage/degradation products. Specifically, in all three cases, this viral protein expression
profile was mainly defined by the following proteins, labeled on the basis of our previous report [12]:
(1) the ~13-kDa C and at least one related smaller product of ~11 kDa (Figure 3A); (2) the ~9-kDa M, its
~24-kDa precursor prM, and notably three prM-related smaller products of 11–19 kDa (Figure 3B);
(3) the ~56-kDa E and at least three related smaller products of 14, 26, and 45 kDa (Figure 3C); (4) the
~45-kDa NS1 (Figure 4A); (5) the ~14-kDa NS2B (Figure 4B); (6) the ~69-kDa NS3, its ~85-kDa cleavage
intermediate NS2B-NS3 or NS3-NS4A/4A’, and multiple NS3-related smaller products of 33–60 kDa
(Figure 4C); (7) the ~14-kDa NS4A’, a further-processed NS4A derivative lacking its C-terminal
transmembrane domain, together with at least two minor proteins NS4Ap29 and NS4ABp35 (Figure 4D);
(8) the ~27-kDa NS4B and at least two related proteins NS4Bp11 and NS4ABp35 (Figure 4E); and (9) the
~103-kDa NS5 (Figure 4F). To our surprise, however, we also noted two previously unrecognized
larger forms of C (Cp14, Figure 3A) and NS1 (NS1p50, Figure 4A), predominantly accumulated in
cells transfected with RNA derived from pZIKV-eGFP or pZIKV-nLUC, but barely detectable in
cells transfected with pZIKV-derived RNA; the nature of the increase in their molecular sizes is
unknown. With respect to viral protein accumulation kinetics, as expected, there was a delay of ~24 h
associated with the two reporter-encoding ZIKVs, which is in good agreement with the increase in
their genome sizes.
Figure 3. Profiling of viral structural protein expression. BHK-21 cells were mock-transfected or transfected
with 2 µg of the infectious RNAs transcribed from pZIKV, pZIKV-eGFP, or pZIKV-nLUC. The cells were
then lysed at 24, 48, 72, or 96 h after transfection. Equal amounts of total cell lysates were resolved by
SDS-PAGE, followed by immunoblotting with one of the following three rabbit antisera specific to the viral
structural proteins: α-C (A), α-M (B), or α-E (C). In parallel, a rabbit α-GAPDH antiserum was used as a
cell lysate loading-control antibody (D). Protein molecular size markers in kDa are indicated on the left,
and major viral structural proteins and GAPDH are marked on the right. White single asterisks indicate
that >90% of cells were detached from the culture plate by virus-induced cell death.
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Figure 4. Profiling of viral nonstructural protein expression. BHK-21 cells were mock-transfected or
transfected with 2 µg of the infectious RNAs synthesized from pZIKV, pZIKV-eGFP, or pZIKV-nLUC.
The cells were then lysed at 24, 48, 72, or 96 h after transfection. Equal amounts of whole-cell lysates
were separated by SDS-PAGE, followed by immunoblotting with one of the following six rabbit antisera
specific to the viral nonstructural proteins: α-NS1 (A), α-NS2B (B), α-NS3 (C), α-NS4A (D), α-NS4B
(E), or α-NS5 (F). Protein molecular size markers in kDa are indicated on the left and major viral
nonstructural proteins are marked on the right. White single asterisks indicate that >90% of cells were
detached from the culture plate by virus-induced cell death.
3.4. Characterization of Reporter Gene Expression During ZIKV Genomic RNA Replication
We examined the expression of a fluorescent or luminescent reporter gene from both the RNAs
derived from our reporter-encoding full-length ZIKV cDNA clones and the viruses recovered from
them. First, we qualitatively determined the production of eGFP in BHK-21 cells at 40 h after RNA
transfection (Figure 5A) and after virus infection (Figure 5B). In both experiments, confocal microscopy
revealed strong green fluorescent signals in the nucleus and cytoplasm, with a notably brighter signal
in the nucleus, not only in the cells transfected with pZIKV-eGFP-derived RNA but also in those
infected with rZIKV-eGFP. The intracellular distribution of the fluorescent signals was consistent with
the fact that the eGFP molecule has a calculated molecular size of ~29 kDa, small enough to be able to
move between the nucleus and the cytoplasm by diffusion. As expected, such fluorescent signals were
not observed in mock-transfected or mock-infected cells, nor were they detected in cells transfected
with pZIKV-derived RNA or infected with rZIKV. Thus, our data show that eGFP is expressed from
both the in vitro-synthesized RNA of pZIKV-eGFP and the viral genomic RNA of rZIKV-eGFP.
Next, we quantitatively evaluated the level of nLUC activity in BHK-21 cells over a 4-day period
following RNA transfection (Figure 5C). To serve as a negative control for the replication-competent
pZIKV-nLUC, we created its replication-incompetent counterpart, pZIKV-nLUCPOL−, by substituting
alanines for the two aspartic acid residues within the conserved GDD sequence motif located
at the catalytic site of the NS5 polymerase domain [67]. In the lysate of cells transfected with
pZIKV-nLUCPOL−-derived RNA, the initial nLUC activity at 6 hpt was 3.0 × 104 relative light
units (RLU), representing the translation of the input RNA in the absence of viral RNA replication.
This level then decreased slowly to 4.0 × 103 RLU at 96 hpt. In the lysate of cells transfected with
pZIKV-nLUC-derived RNA, on the other hand, the initial nLUC activity at 6 hpt was 3.6 × 104 RLU,
a level slightly higher than that obtained at the same time point from pZIKV-nLUCPOL−-derived RNA.
In this case, the level then increased rapidly to 7.3 × 106 RLU by 48 hpt and peaked at 4.7 × 107 RLU at
72 hpt. As expected, no nLUC activity above the background of cellular luminescence was detected
in the lysate of mock-transfected cells or cells transfected with pZIKV-derived RNA. These results
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demonstrate that nLUC is expressed from the in vitro-synthesized RNA of pZIKV-nLUC in a manner
dependent on viral RNA replication.
We also measured the activity of nLUC for 4 days after the infection of BHK-21 cells with
rZIKV-nLUC to confirm the reporter expression from the incoming viral genomic RNA (Figure 5D).
For this experiment, BHK-21 cells were mock-infected or infected with rZIKV-nLUC or rZIKV as a
control at a MOI of 1. In the lysate of cells infected with rZIKV-nLUC, the initial nLUC activity at
6 h post-infection (hpi) was 7.3 × 103 RLU, dropping temporarily to 3.8 × 103 RLU at 12 hpi before
substantially accumulating newly synthesized genomic RNAs, but then increasing sharply and peaking
at 2.2 × 107 RLU at 60 hpi. As expected, neither mock-infected nor rZIKV-infected cells exhibited any
nLUC activity above the background level. Therefore, our results indicate that nLUC is expressed from
the viral genomic RNA of rZIKV-nLUC and its expression level increases as the replication progresses.
Figure 5. Monitoring of reporter gene expression. (A,B) eGFP expression. BHK-21 cells were
mock-transfected or transfected with 2 µg of the in vitro-transcribed RNAs from pZIKV or pZIKV-eGFP
(A). In parallel, BHK-21 cells were mock-infected or infected with rZIKV or rZIKV-eGFP at a multiplicity
of infection (MOI) of 1 (B). At 40 h post-transfection (hpt) or post-infection (hpi), cells were fixed and
examined by confocal microscopy. Images were acquired using a 20X dry lens (Plan-Apochromat 20X/0.8
M27). Representative fluorescent images from one of two experiments are presented. (C,D) nLUC
activity. BHK-21 cells were mock-transfected or transfected with 2 µg of the in vitro-synthesized RNAs
of pZIKV, pZIKV-nLUC, or pZIKV-nLUCPOL− (C). In addition, BHK-21 cells were mock-infected or
infected with rZIKV or rZIKV-nLUC at a MOI of 1 (D). During the incubation period of 4 days, cells
were lysed at the indicated time points after RNA transfection or virus infection for nLUC assays.
The nLUC activity is expressed in relative light units (RLU). Error bars indicate standard deviations of
two independent experiments.
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3.5. Examination of the Viral Growth and Stability of Two Reporter-Expressing ZIKVs
We assessed the growth kinetics of our two reporter-expressing ZIKVs in BHK-21 cells following
infection at a MOI of 1 with rZIKV-eGFP or rZIKV-nLUC, or with rZIKV for comparison; viral titers were
determined by immunofocus assays on naïve BHK-21 cells by using a rabbit α-NS3 antiserum. During a
4-day incubation period, rZIKV initially displayed a short eclipse phase, with a titer of 3.5× 103 FFU/mL at
12 hpi; this phase was followed by a sharp burst phase, reaching a titer of 1.9 × 106 FFU/mL by 24 hpi and
peaking at 1.3 × 107 FFU/mL at 48 hpi (Figure 6A). On the other hand, both rZIKV-eGFP and rZIKV-nLUC
uniformly showed a delay of ~24 h in viral growth, with their eclipse phases lasting until 18 hpi and
achieving their peak titers of 6.5–8.0 × 106 FFU/mL at 72 hpi (Figure 6A). Thus, our data show that our
two reporter-expressing ZIKVs grow to a high titer, but more slowly than their parent rZIKV.
Figure 6. Characterization of viral growth and stability. BHK-21 cells were infected at a MOI of 1
with rZIKV, rZIKV-eGFP, or rZIKV-nLUC. (A) Viral growth. Culture supernatants were collected at
the indicated time points after infection for 4 days to determine the accumulation level of infectious
progeny virions by immunofocus assays on naïve BHK-21 cells. The data represent mean values,
and the error bars show standard deviations. (B) Viral stability. Presented are representative images
of the infectious foci formed by the infectious progeny virions that were harvested at 24, 48, or 96 h
post-infection (hpi). Mock-infected cells were included as a negative control.
During the analysis of viral growth kinetics, we also monitored the morphology of infectious
foci developed by the progeny virions that were released over a period of 4 days from BHK-21
cells infected with rZIKV-eGFP, rZIKV-nLUC, or rZIKV. The homogenous, large foci generated by
rZIKV remained unchanged for the entire 4 days (Figure 6B). However, the homogenous, tiny foci
produced by rZIKV-eGFP and rZIKV-nLUC both exhibited marked visible changes, increasing in both
size and heterogeneity over time, with the new foci becoming as large as those formed by rZIKV
(Figure 6B). These phenotypic changes are indicative of genetic instability in the two reporter-expressing
ZIKVs. Indeed, both rZIKV-eGFP and rZIKV-nLUC nearly lost their ability to express their respective
reporter genes after five serial passages of each virus in BHK-21 cells at a MOI of 1 (data not shown).
Therefore, our results indicate that our two reporter-expressing ZIKVs, directly recovered from their
respective cDNA clones, contained their functional reporter expression cassettes; however, in both
cases, the inserted reporter expression cassette became non-functional during subsequent propagation
in cell culture.
3.6. Evaluation of the Antiviral Activity of Three Compounds Using rZIKV-nLUC
We utilized a stock of the unpassaged rZIKV-nLUC virus directly recovered from its functional
cDNA clone to compare the in vitro anti-ZIKV activity of three different nucleoside analogs
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that can act as a substrate for the viral NS5 (Figure 7): (i) the purine analog T-705, also
known as favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) [68–72]; (ii) the adenosine analog
NITD-008 (7-deaza-2′-C-acetylene-adenosine) [73–75]; and (iii) the guanosine analog ribavirin
(1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) [68,69,72,76]. To this end, BHK-21 cells were
mock-infected or infected with rZIKV-nLUC at a MOI of 0.1 in a 96-well plate and incubated in the
absence or presence of each nucleoside analog at four different concentrations that had little or only
moderate cytotoxic effects on the cell line (Figure 7A). At 48 h after infection, culture supernatants were
harvested to examine the production level of extracellular infectious virions and cell monolayers were
lysed to analyze the expression level of intracellular nLUC as an indicator of viral RNA replication.
We observed that all three nucleoside analogs exhibited a dose-dependent inhibition of the production of
progeny virions in the presence of increasing amounts of each compound (Figure 7B). More importantly,
this decrease in virus production was directly correlated with the reduction in nLUC expression
(Figure 7C). It was also noted that treatment with NITD-008 at 100 µM or ribavirin at 1000 µg/mL
equally produced a complete inhibition of viral RNA replication and consequently, virus production
(Figure 7B,C). Taken together, these results demonstrate the feasibility of using reporter-expressing
ZIKVs to facilitate the screening and testing of new antiviral drugs against this pathogen.
Figure 7. Application of rZIKV-nLUC for testing antiviral compounds. (A) Cell toxicity. BHK-21 cells
were treated with T-705 (0, 1, 4, 20, and 100 µg/mL), NITD-008 (0, 1, 4, 20, and 100 µM), or ribavirin (0,
8, 40, 200, and 1000 µg/mL) for 48 h. At the end of the incubation, cell viability was measured using the
CellTiter-Blue Cell Viability Assay. (B,C) Antiviral activity. BHK-21 cells were mock-infected or infected
with rZIKV-nLUC at a MOI of 0.1 and treated with T-705, NITD-008, or ribavirin at one of the indicated
concentrations for 48 h. Antiviral activity was analyzed with regard to both the level of extracellular
virus production in culture supernatants using our α-NS3 antibody-based immunofocus assay (B) and
the level of intracellular nLUC expression in cell lysates using the Nano-Glo Luciferase Assay (C).
The data represent mean values, and the error bars show standard deviations. ND, Not detectable.
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4. Discussion
In this report, we describe the development of two reporter-encoding full-length functional cDNA
clones of ZIKV: pZIKV-eGFP, which encodes an enhanced green fluorescent protein, and pZIKV-nLUC,
which encodes an improved luminescent NanoLuc luciferase. In both cases, transfection of
ZIKV-susceptible BHK-21 cells with run-off RNA transcripts synthesized in vitro by SP6 RNA
polymerase from the PsrI-linearized cDNA template resulted in the production of reporter-expressing
ZIKVs, although the insertion of such a reporter expression cassette into the viral genome caused a
delay in viral RNA replication, protein accumulation, and eventually, virus production when compared
to parental ZIKV. Interestingly, a series of immunoblotting experiments with each of nine ZIKV
region-specific polyclonal rabbit antisera identified two previously overlooked larger forms, each
related to C and NS1, both of which accumulated to readily detectable levels in cells transfected with
the RNA transcribed from pZIKV-eGFP or pZIKV-nLUC, but only to barely detectable levels in cells
transfected with the parental pZIKV-derived RNA. We also employed our nLUC-expressing ZIKV as a
platform to assess the antiviral activity of three nucleoside analogs, T-705, NITD-008, and ribavirin.
Taken together, our two reporter-expressing ZIKVs and their functional cDNA clones provide useful
molecular tools not only for the study of viral infection/replication, but also for the development of
antiviral drugs [77,78].
We created two reporter-encoding full-length functional cDNA clones of ZIKV MR-766 based on a
BAC plasmid [79], a single-copy vector that has enabled us to maintain a genetically unstable full-length
ZIKV cDNA [12] and has been shown to minimize the destabilizing effects on other full-length flavivirus
cDNAs [80] that occur during its amplification in E. coli with multiple-copy vectors [81–85]. Using our
two reporter-encoding full-length ZIKV BAC clones, we produced reporter-expressing viruses by
employing a single plasmid-based “RNA-launched” reverse genetic approach, which involved the
transfection of infectious RNA transcripts synthesized from a full-length ZIKV cDNA that is flanked
by a phage SP6 promoter at the 5′ end and a unique PsrI restriction site at the 3′ end for in vitro run-off
transcription. Following RNA transfection, the infectious ZIKV RNAs, like the viral genomic RNA,
directly underwent viral translation and RNA replication in the cytoplasm of the transfected cells.
Several conceptually similar RNA-launched systems have previously been developed to construct a
full-length functional ZIKV cDNA clone, based on a single- or low-copy vector. For these, a combination
of a 5′ phage promoter (SP6 or T7) with either a 3′ unique recognition site for one of three restriction
endonucleases (AgeI, XhoI, and BssHII) or a 3′ self-cleaving ribozyme sequence of hepatitis delta virus
(HDVr) has been used [26,67,86–89]. These systems have been employed to generate recombinant
ZIKVs expressing one of the following seven reporters: one of three fluorescent proteins (eGFP,
mCherry, or turboFP635) or four luciferases (Photinus, Renilla, Luciola, or NanoLuc) [67,86,87], as
well as replication-competent but propagation-deficient subgenomic replicons expressing one of two
luciferases (Renilla or Gaussia) [67,87,89–91].
Although the system we describe in the present study is conceptually similar to all the other single
plasmid-based RNA-launched systems reported previously, there are two key technical differences:
(i) Our study produced reporter-expressing ZIKVs with an EMCV IRES-driven reporter gene expression
cassette inserted downstream of the single ORF of the ZIKV genome. Therefore, the level of reporter
gene expression depended on the actual number of viral genomic RNAs during the replication process,
although its translation was controlled by the EMCV IRES element. In contrast, all the previous studies
have introduced a particular reporter gene in-frame after a partial or complete sequence of the viral C
protein that contains a cis-acting cyclization sequence required for viral RNA replication, followed
in-frame by the foot-and-mouth disease virus (FMDV) 2A autoprotease sequence and then the entire
ZIKV ORF that contains a functional or non-functional cyclization sequence within its C protein-coding
region [67,86,87,89–91]. The resulting reporter-expressing ZIKVs therefore have a reporter-FMDV
2A gene segment placed in-frame upstream of the viral ORF under the control of its own 5′UTR.
(ii) It is noteworthy that in our current study, for cDNA linearization, we applied the extremely
rare-cutting restriction endonuclease PsrI (N7↓N12GAACN6TACN12↓N7), which cuts on both sides
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of its recognition sequence after any nucleotide. The application of PsrI is highly advantageous not
only because it was far less likely to find a preexisting site(s) in the viral genome than were most
site-specific restriction endonucleases, of which their recognition sequences are from four to eight bases
long, but also because we could generate synthetic RNAs with the authentic 3′ end of the viral genome
by run-off transcription of the PsrI-linearized full-length ZIKV cDNA. In the previously reported
systems, however, a full-length functional ZIKV cDNA clone has been linearized either by using one
of three six-base-recognizing classical type II endonucleases (AgeI, XhoI, or BssHII), all of which leave
five non-viral extra nucleotides at the 3′ end of in vitro-transcribed full-length RNAs [26,67,87,88],
or by using the ~85-nt self-cleaving ribozyme HDVr, which generates the authentic viral 3′ end [86,89],
as was accomplished in our study by using the bipartite seven-base-recognizing unusual type IIB
endonuclease PsrI. Creating the authentic 3′ end is of particular importance because this reaction has
been shown to be critical for the production of infectious ZIKV RNAs [12].
As an alternative to the RNA-launched approach, a single plasmid-based “DNA-launched”
approach has been developed to recover infectious ZIKVs from a cloned cDNA. This alternative
process involves the transfection of a single- or multiple-copy vector carrying a full-length infectious
ZIKV cDNA that is flanked at the 5′ end by an eukaryotic RNA polymerase II (Pol II)-dependent
cytomegalovirus promoter and at the 3′ end by an HDVr sequence plus a simian virus 40-derived or
bovine growth hormone gene-derived polyadenylation signal and transcription terminator [87,92–94].
In most cases, the full-length ZIKV cDNA has been engineered to include an artificial intron(s) to
circumvent its genetic instability during propagation in bacteria [87,92,93]. Following DNA transfection,
the infectious ZIKV cDNAs are initially transcribed in the nucleus of transfected cells by cellular
RNA Pol II and the primary transcripts are processed and transported to the cytoplasm, where
viral RNA replication takes place. This vector-oriented system has been modified to develop two
non-vector-oriented systems: The first requires the transfection of a circular full-length ZIKV cDNA
that is synthesized by a circular polymerase extension cloning method using a mixture of eight
overlapping cDNA fragments [95]. The second requires the co-transfection of three or four overlapping
cDNA fragments, which are eventually joined into a linear full-length ZIKV cDNA by spontaneous
recombination in the transfected cell, although inefficiently [96,97]. Of these two new systems,
the second one has been used to generate GFP-expressing ZIKVs by introducing the GFP-FMDV 2A
gene segment in-frame, downstream of a partial sequence of the ZIKV C protein, followed in-frame by
the entire ZIKV ORF [97].
Reporter-expressing viruses provide a powerful tool not only for the detection and analysis of viral
replication, but also for the screening and testing of antiviral agents without specific labeling of viral
components [77,78]. In this study, we utilized both the fluorescent eGFP and the luminescent nLUC
as reporters for ZIKV because each reporter offers particular benefits that are useful for prospective
applications. First, a fluorescent protein facilitates single-cell analysis by enabling the tracking of
infected individual cells. One of the main applications of fluorescent protein-expressing ZIKVs is
fluorescence-activated cell sorting (FACS) analysis, in which cells are separated using a flow cytometer
based on the presence or absence of a fluorescent signal [98]. Recently, this method has been shown to
be useful in testing potential antivirals against ZIKV, since the number of GFP-positive infected cells
decreases when they are treated with a known flavivirus inhibitor such as ribavirin or interferon-β [97].
In the case of the luciferase reporter, the ability to quantify enzyme activity in a simple manner has
led to its common use as a reporter in various flaviviruses to expedite the discovery process of novel
antivirals. One of the primary means by which this discovery has been accomplished is through the
optimization of a high-throughput assay with the use of luciferase-expressing ZIKV [86] and other
flaviviruses (e.g., DENV and WNV) [99–102]. The present study took advantage of nLUC, an improved
version of luciferase that can provide an advanced screening platform empowered by a higher reporter
protein stability, a lower detection limit, and a broader dynamic range than traditional Photinus and
Renilla luciferases [66]. In particular, the higher stability of nLUC was highlighted by our results
described in this study, demonstrating that there were no significant decreases in its activity for the first
Viruses 2020, 12, 572 16 of 24
48 h after transfection of the replication-incompetent pZIKV-nLUCPOL−-derived RNA into BHK-21
cells. By comparison, an analogous recombinant JEV expressing the Photinus luciferase developed by
our laboratory exhibited a nearly 2-log decrease in luciferase activity over the same time span under
identical experimental conditions [60]. This improved stability of nLUC offers a relatively long time
window to more precisely quantify an inhibitory effect of potential antiviral compounds against ZIKV.
In this study, we showed the usefulness of nLUC-expressing ZIKV in testing three nucleoside analogs
in vitro as potential antivirals, which can act as a substrate for the ZIKV NS5. Given the fact that several
recombinant viruses expressing a luciferase gene are often used for in vivo bioluminescence imaging
to visualize the sites of viral infection and replication and monitor the dynamics of viral spread in live
animals [77,103], this optical molecular imaging technique might also be a potential application for an
improved version of our nLUC-expressing ZIKV with a higher genetic stability in future studies.
As is often the case with reporter-expressing flaviviruses [78,80], our results indicate that the
insertion of a reporter gene into the genome of ZIKV led to an attenuation of viral replication and
a decrease in genetic stability. The larger genomes resulted in slower replication which, in turn,
created a selective pressure for the reporter-expressing ZIKVs to delete all or part of the inserted
reporter gene that is unnecessary for viral replication. As noted previously [87,97], we observed
signs of this deletion occurring after serial passage of rZIKV-eGFP and rZIKV-nLUC, with their
infectious foci formed on monolayers of BHK-21 cells growing in size and becoming increasingly
heterogeneous over time. Despite the long-term genetic instability of their viral genomes, we were
able to recover reporter-expressing ZIKVs for the first 4 days after transfection of infectious RNAs
transcribed in vitro from the respective cDNAs. Our choice to insert a reporter gene after the stop
codon of the ZIKV ORF was based on our previous work with JEV showing that such placement
had less of a negative impact on viral replication than did the placement of a reporter gene before
the start codon of the viral ORF [60,104]; a similar strategy has also been shown to be effective in
generating reporter-expressing WNV [105,106] and DENV [107,108]. Interestingly, however, it appears
that our eGFP- and nLUC-expressing ZIKVs described in the present study showed greater levels of
genetic instability than have the similar GFP- and luciferase-expressing JEVs previously developed
by our laboratory [60,104]. An alternative approach commonly employed in the development of
reporter-expressing flaviviruses is to place a reporter gene upstream of the viral full-length ORF, such
as with WNV [109], DENV [99,110–112], and ZIKV [67,86,87,97]. In all these cases, reporter-expressing
flaviviruses are genetically unstable, eventually losing the ability to express the reporter gene. Further
work, including new approaches, is necessary to produce genetically stable reporter-expressing ZIKVs
and other flaviviruses [113–116].
For both the eGFP- and nLUC-expressing ZIKVs we generated in this study, the translation
of each reporter gene was driven by an IRES element. Of several known viral IRESs, we chose to
use an EMCV IRES, not only because it has a stronger activity in terms of internal ribosomal entry
than do other IRESs, including those from poliovirus, rhinovirus, foot-and-mouth disease virus,
and hepatitis A and C viruses, but also because it is biologically functional in a variety of cell types,
unlike those from poliovirus and rhinovirus [117,118]. Since the 619-nt version of the EMCV IRES
that we used in the present study is quite long, it significantly increased the size of the viral genome
and decreased the efficiency of viral replication. In the future, as a way of improving the genetic
instability of our reporter-expressing ZIKVs, we can consider utilizing a shorter version of the EMCV
IRES that contains only an ~450-nt core sequence for IRES function or employing one of the shorter
IRESs, such as those from picornaviruses (~450 nt), hepatitis C virus (~350 nt), and cricket paralysis
virus (~190 nt) [119,120]. Interestingly, a recent study has shown that the relatively short 5′UTR of
the genomic RNA of two flaviviruses, i.e., DENV (~100 nt) and ZIKV (~110 nt), has IRES activity
capable of directing the cap-independent internal initiation of translation [121]. Because of its short
length and IRES activity, this 5′UTR would be a good candidate for the construction of IRES-driven
reporter-expressing recombinant ZIKVs to improve our system.
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Our reporter-expressing ZIKVs were developed as a bicistronic expression vector by keeping the
single viral ORF under the cap-dependent translational control of its own 5′UTR as the first cistron and
inserting the eGFP or nLUC gene under the cap-independent translational control of EMCV IRES as the
second cistron at the end of the viral ORF. The insertion of such a reporter gene expression cassette into
the viral genome increased the genome length, which led to a decrease in viral RNA replication. In a
study using a similar IRES-mediated bicistronic expression vector designed for co-expression of two
reporter genes, an inverse correlation has been demonstrated between the expression of one reporter
and the other, suggesting a competition between the two coding sequences during translation [122].
Based on this previous study, we can expect that the high expression of the viral ORF will lower
the expression of a reporter gene and vice versa. In addition, this earlier study also found that the
translational competition is dependent on the size of the two genes [122]. In the present study, therefore,
the viral ORF has a competitive disadvantage relative to the reporter gene, which inevitably leads to a
decreased expression of viral proteins when compared to the same virus without a reporter gene. As a
consequence, the lower replicative ability of our reporter-expressing ZIKVs is likely not only a result of
the longer genome length, but may also be linked to the lower expression of viral proteins resulting
from the presence of a reporter gene.
Immunoblot analysis revealed that the viral protein accumulation profiles generated from each of
the eGFP- and nLUC-expressing ZIKV RNAs were similar to those produced from the parental ZIKV
RNA with no reporter gene expression cassette, which is in agreement with our previous work [12].
The panel of nine ZIKV antigen-specific polyclonal rabbit antisera that we employed in this study
detected all of the expected viral proteins for the parental and reporter-expressing ZIKV RNAs, but
the kinetics of protein accumulation was delayed by ~24 h in the latter case. This delay was in line
with the reduced viral growth rates and focus sizes. Beyond these similarities, we also found that
immunoblotting with the α-C and α-NS1 antisera revealed a significant accumulation of two previously
undescribed protein species (Cp14 and NS1p50) expressed from each of the two reporter-expressing
ZIKV RNAs. Although the nature of these two proteins is unknown, our data enable us to make
several inferences about their identity: (i) The fact that Cp14 and NS1p50 were strongly stained in
cells harboring eGFP- or nLUC-expressing ZIKV RNA suggests that their accumulation is a result of
changes caused by the insertion of a reporter gene expression cassette into the viral genome, not by the
presence of either eGFP or nLUC specifically. (ii) It is unlikely that Cp14 and NS1p50 correspond to
any unknown degradation products of C and NS1, respectively, because Cp14 (~14 kDa) is larger than
C (~13 kDa) and NS1p50 (~50 kDa) is larger than NS1 (~45 kDa). (iii) Cp14 cannot be the result of a
non-canonical cleavage at the C-prM junction because there were no unexpected or altered protein
bands present on the immunoblot stained with the α-M antiserum, which would be detectable in the
event of alternate processing at the C-prM junction of the viral polyprotein. The same possibility of any
non-canonical cleavage at the NS1-NS2A junction cannot be ruled out in the case of NS1p50 because
there is no antibody currently available to detect ZIKV NS2A [12]. (iv) It is less likely that NS1p50
corresponds to NS1′, a C-terminally extended variant of NS1 that results from a -1 ribosomal frameshift
occurring at codons 8–9 of NS2A in JEV and WNV infection [63,123–125], because ZIKV lacks two
genetic elements, a slippery sequence and a predicted pseudoknot, required for the frameshifting (see
Supplementary Figure S1). We therefore speculate that Cp14 and NS1p50 are the result of unknown
post-translational modifications of C and NS1, respectively. Given that both Cp14 and NS1p50 were
faintly detectable in cells harboring the parental ZIKV RNA, it is possible that the slow replication
of eGFP- and nLUC-expressing ZIKV RNAs and the resulting delay in virus-induced cell death may
allow for the accumulation of these two previously unrecognized viral proteins.
In sum, the present study presents the development, characterization, and application of two
reporter-expressing ZIKVs. These recombinant viruses are replication-competent, expressing the
fluorescent eGFP or luminescent nLUC protein in a manner dependent on viral RNA replication.
Therefore, these recombinant viruses represent useful additions to the molecular tools currently
available to the ZIKV research community, facilitating the advancement of our understanding of ZIKV
Viruses 2020, 12, 572 18 of 24
infection/replication. Also, our two reporter-expressing ZIKVs can be instrumental in the development
of novel antiviral agents.
Supplementary Materials: The following is available online at http://www.mdpi.com/1999-4915/12/5/572/s1,
Figure S1: ZIKV lacks the ribosomal frameshift signal directing the expression of NS1′.
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